Editas Medicine stockholders approve increase in authorized shares and amend 2015 Stock Incentive Plan at annual meeting

Editas Medicine, Inc.

Stockholders approved amendment to increase authorized common stock from 195M to 390M shares; total capital stock from 200M to 395M.
Stockholders approved amendment and restatement of 2015 Stock Incentive Plan, extending term to 10 years and eliminating evergreen provision.
Re-elected Jessica Hopfield, Ph.D., and David Scadden, M.D. as Class III directors until the 2028 annual meeting.
Advisory vote on executive compensation passed with ~60% for; one-year frequency for future say-on-pay votes approved.
Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Editas Medicine, Inc.: Increased authorized shares of capital stock from 200,000,000 to 395,000,000 and common stock from 195,000,000 to 390,000,000 (effective 2025-06-02).

Change: charter amendment
Effective: 2025-06-02

Exact text from the filing

At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s capital stock from 200,000,000 to 395,000,000 and the number of authorized shares of the Company’s common stock from 195,000,000 to 390,000,000. The additional common stock authorized by the Certificate of Amendment has rights identical to the Company’s currently outstanding common stock. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 2, 2025.

View on SEC.gov

Browse all governance changes →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-25-000086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.